Jeito Capital, a global investment company, and RA Capital, a multi-stage investment manager, led a $76m Series A funding round in CDR-Life, a developer of cancer treatments, with participation from Omega Funds. “We are honored to have the support of these high-caliber investors, reflecting both the critical need for effective T cell engaging therapies against solid tumors and the support of the CDR-Life product engine and development pipeline. The proceeds from this financing allow us to fund our first clinical proof-of-concept opportunity with CDR404, while continuing development of novel targeted immunotherapies based on CDR-Life’s superior T cell engaging platform," Christian Leisner, CDR-Life CEO.